Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01790854Phase 4Terminated

BLeeding Events and Maintenance DoSe of PraSugrel

Role: collaborator

NCT01992523Phase 3Completed

Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )

Role: collaborator

NCT01805570Phase 4Completed

Rapid Activity of Platelet Inhibitor Drugs Study 2

Role: collaborator

All 3 trials loaded